Tilray’s Medical Marijuana Extract Shows Promise in Reducing Chemotherapy Side Effects
Tilray Medical, a division of medical marijuana giant Tilray Brands, Inc., has unveiled promising results from a new scientific study that explored the effectiveness of oral cannabis extract in managing chemotherapy-induced nausea and vomiting (CINV). The study, titled “Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV),” demonstrated that cannabis extract significantly reduced CINV, offering a potential new avenue for managing this debilitating side effect for cancer patients.
“These findings are encouraging for cancer patients undergoing chemotherapy,” stated Denise Faltischek, chief strategy officer and head of international at Tilray Brands. “This study is a crucial step in improving patient care and quality of life. Our involvement in this study underscores our commitment to advancing medical research. The positive outcomes highlight the potential of cannabinoids for managing CINV.”
The Study’s Key Findings
The randomized, placebo-controlled trial involved adults experiencing CINV despite standard anti-nausea treatments. Participants received capsules containing 2.5 mg of THC and 2.5 mg of CBD or a placebo, administered three times daily for six days. The results were significant: the cannabis extract boosted the complete response rate from 8% with placebo to 24% with THC: CBD, without the need for additional medications. Participants using the cannabis extract also reported reduced nausea and fewer daily vomits.
While the study demonstrated positive outcomes, some side effects were observed, including sedation (18% vs. 7%), dizziness (10% vs. 0%), and transient anxiety (4% vs. 1%).
Tilray Launches ‘Men’s Health on Tap’ Podcast
In a separate initiative, Tilray Brands has launched “Men’s Health on Tap,” a new podcast series designed to break down stigmas and foster open dialogue surrounding men’s health issues. The podcast features two medical experts: Dr. John P. Sfakianos, MD, associate professor, Department of Urology at the Icahn School of Medicine, and Dr. Steven A. Kaplan, MD, professor, Department of Urology at the Icahn School of Medicine.
Sfakianos and Kaplan recognize the hesitancy many men have in discussing health concerns, often leading to delayed visits to the doctor and potentially serious undiagnosed conditions. Episode one of the podcast encourages men to openly address health issues and emphasizes the importance of regular check-ups and early intervention for a healthier and longer life.
“We are excited to launch ‘Men’s Health on Tap’ and break down stigmas around men’s health,” stated Sfakianos. “Our goal is to provide valuable information and resources that will help men take control of their health and wellness.”
Tilray’s Stock Performance
Tilray shares experienced a 1.30% increase to $1.56 per share during Thursday’s pre-market session, reflecting the positive news surrounding the company’s research and initiatives.
